Reduction of ara-C cytotoxicity in HL 60 cells by addition of deoxycytidine, cytidine or increased level of cytidine deaminase.
Mejer
J
J
Finsen Institute, Laboratory of the Medical Department, Copenhagen, Denmark.
Mortensen
B T
BT
D001853:Bone Marrow / Q000201:enzymology; D001854:Bone Marrow Cells; D002455:Cell Division / Q000187:drug effects; D003561:Cytarabine / Q000633:toxicity*; D003562:Cytidine / Q000494:pharmacology*; D003564:Cytidine Deaminase / Q000378:metabolism*; D003841:Deoxycytidine / Q000494:pharmacology*; D003842:Deoxycytidine Kinase / Q000378:metabolism*; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000378:metabolism* / Q000473:pathology; D009700:Nucleoside Deaminases / Q000378:metabolism*; D010770:Phosphotransferases / Q000378:metabolism*; D013767:Tetrahydrouridine / Q000494:pharmacology; D014212:Tretinoin / Q000494:pharmacology; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000378:metabolism
D003561:Cytarabine; D003841:Deoxycytidine; D013767:Tetrahydrouridine; D014212:Tretinoin; D003562:Cytidine; D010770:Phosphotransferases; D003842:Deoxycytidine Kinase; D009700:Nucleoside Deaminases; D003564:Cytidine Deaminase